Parkwalk Advisors

"We are delighted to close out this first phase of our investment round with the support of Parkwalk and Maven. Maven are joining us at what is a very exciting time in our journey as we head towards a new chapter. Having worked with Parkwalk for 6 years, it’s fantastic to carry on our strong relationship as we deliver on our ambitious plans. The growth we have seen in recent years is a testament to our market leading innovation and we can’t wait to use this investment to take the business to the next level."

"Our semiconductor-based approach is fundamentally reshaping what neural implants can achieve. By offering a customisable, compact solution that integrates seamlessly into medical devices, we’re empowering a new era of neural interfaces that are not only more powerful but also less invasive. This marks a transformative shift in neurological care."

"There is a massive market opportunity for start-ups that figure out how to harness the potential of AI to transform how software gets built, tested, and deployed. Our investment in the company reflects our belief in its potential to be an important player in the next generation of AI-powered software development tools."

"Smell can be our most powerful sense and only now are we realising the potential of technology to translate it for experience, welfare and health. This technology has enormous commercial applications which this new investment will help us unlock."

"Medical devices follow a lengthy evaluation with a tiny amount of scientific evidence currently derived from computer modelling and simulation. The cost is ever-increasing, delaying lifesaving benefits to patients. Northern Gritstone’s and Parkwalk’s investment and support will enable adsilico to offer a scalable solution to the medical device market to produce evidence on an unprecedented scale"

"We are delighted to receive the continued support of Astellas Venture Management, Parkwalk Advisors and other existing investors as we relentlessly focus on progressing our novel pipeline of in vivo reprogramming therapies through pre-clinical translation. Aligned to a consolidated corporate structure and vision, this latest funding will provide sufficient cash runway to enable the achievement of key development milestones in both our internal programs as well as those being developed in collaboration with strategic partners. Existing investor commitment is a testament to our delivery of world-class science, expertise in cellular reprogramming and the unique potential of the MOGRIFY platform to deliver novel regenerative medicines to improve the lives of a broad spectrum of patients."

"For scaling companies, keeping track of terms across hundreds or thousands of contracts is a challenge that creeps up on you. Searching for basic information like contract start and end dates, or nuances in confidentiality terms across entire databases of contracts is painfully manual, or impossible. Before working with us, we know that some of our customers would spend weeks doing this"

"The support of leading technology investors enables us to realise our vision of a quantum computer built using standard foundry processes. This support, along with the continuing UK national quantum programme and European initiatives, provides a step-change in our capabilities. We have assembled a world leading team and with the funding and support in place, we are ready to scale and deliver on our vision."

"CGD is poised to become one of the leaders in enabling a sustainable world. As we move to a net-zero carbon society with rapidly increasing levels of electrification, we need clean, renewable sources of electricity and more efficient conversion methods. GaN provides the optimum conversion solution, reducing power losses by more than 50% and increasing energy conversion efficiency to above 99%. To take just one application example, if all data centres were to adopt GaN, this would save 12.4TWh of electricity per year, or 9 million tons of CO2 – the equivalent of taking 1.9 million internal combustion engines vehicles off the road for a year *. Our ICeGaN™ GaN transistors – which are now in the hands of customers at scale – are amongst the most efficient devices of their type on the market. Our devices are also the easiest for designers to use."

"These are incredibly exciting times for the genomics community and we are proud to pioneer the advent of a new era for patient-centric medicine. We are delighted to have the support of BGF, Parkwalk and our existing investors Bioqube and Jonathan Milner, which provides validation of our technology platform, GenLink3DTM."

"Global agriculture needs a new Green Revolution if we are to feed the world sustainably. Being able to control weeds is critical to both yield and the cost of production in most crops and new herbicide modes of action are essential. It’s very exciting to see moa starting to play its part in this new revolution by advancing so far in such little time."

"However, due to resource costs and poor logistics, current health systems cannot deliver the amount of therapy needed, with significant backlogs, and few patients receiving anywhere near what they require to get better. This is a common problem faced by hundreds of millions of patients around the world, with inefficient care pathways not only costing health systems hundreds of billions of dollars every year, but costing people a chance to live their lives to their full potential."

"We are looking to interrupt a marketplace dominated by technologies reliant solely on sound, vision and increasingly, touch. Our sense of smell has the power to evoke long-forgotten memories, bring food to life, calm us down and enrich our lives. We create smell technologies that can be used across a range of innovative contexts. From leading healthcare research to artistic and immersive experiences, our products offer a total digital command over scent and smell."

"Hydrogen, through its green production from electrolysis or its use in fuel cells to provide clean power, is critical for the transition to net zero. Bramble Energy brings a fundamentally different approach to these technologies, unlocking the deployment of hydrogen faster, more flexibly and at scale. We are delighted to contribute substantially to this significant funding round which will take Bramble to the next stage."

"Over the past decade Brainomix has created the market for stroke AI imaging. As a spin-out from the University of Oxford it is an example of the UK's world-leading strengths in life sciences and AI-enabled medtech, combining expertise in clinical care and software development with more than 150 years' experience in the field across its leadership team."

"We are delighted to see the continued support of our existing investors, as well as welcome new investors Astellas Venture Management and Dr Jonathan Milner, in support of the progression of our initial programs through to IND-enabling studies."

"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."

"We are thrilled to include this exceptional group of investors in PhoreMost’s Series B funding round. We are grateful for the continued support of existing investors and are delighted to welcome BGF, alongside strategic investors XtalPi with whom we have a highly valued ongoing research collaboration, and Astellas Venture Management."

"This funding will help us accelerate product development and go to market in the UK. Since launching our closed-beta service in June 2020, we have organically doubled our user base every month. We now have more than 800 users, including a handful of early adopters of our paid subscription. Simple legal documents, such as NDAs and tenancy agreements, can be surprisingly frustrating and time-consuming to create, negotiate, and manage, wasting valuable time for landlords and small businesses who don’t have in-house or retained legal support. We saw an opportunity to apply knowledge graph technology to the problem and create a delightful, streamlined contracting experience."

"This latest round of investment is a great recognition of our success to date, with new and existing investors confirming the strength of our technology. Since 2016, CGD has grown significantly and we are thrilled to be in a position to deliver several products to market, following decades of industry-leading research in reliability of power devices. This investment will allow us to supplement our experienced team with additional experts and expand our markets globally, creating more sustainable electronics worldwide."

"Already in the past two years quantum hardware has surpassed expectations, achieving milestones that seemed decades away. By pioneering new advances in quantum software, Phasecraft can take quantum theory from research to reality, faster. With new funding and supporters, we can be part of building the foundations of the quantum computing industry, making useful applications available quicker than ever thought."

"This funding will help us reach new retailers and further support our existing clients in addressing the challenges and opportunities of selling and advertising in a competitive and fast-growing marketplace. The application of machine learning, and the fusion of transactional data with media data, brings brands huge advantage in the Amazon environment, extracting maximum commercial value and sales performance. Our platform is at the forefront of unlocking this potential for international retailers."

"There are some technologies that can change a small part of the insurance value chain, but there are no technology companies that can help insurers transform the entire insurance operation. Therefore, we had been seeking a reliable partner with first-class technology in order to jointly develop such solutions across the insurance value chain."

"The energy efficiency of many products could be greatly improved if they incorporated gas and flow sensors, but companies are unable to do so due to cost, size, or manufacturing constraints. Our vision is to bring flow- and gas-sensing technologies to all these products. This funding round helps us to scale up and bring our vision to reality."

"We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials."

"We have been tracking YASA’s progress for a number of years and are pleased to have the opportunity to invest in one of the UK’s most exciting high-growth technology companies that is well positioned to take advantage of the rapid move to electrification in both automotive and aerospace sectors."

"Weeds are now a greater threat to crop yields than at any time in recent decades. New solutions are urgently needed. Raising £6m at this stage in the company’s development is a real testament to the strength of the company’s prospects."

"In addition, we can now begin to penetrate international markets. The deepening of our relationship with DCHealth gives us greater insight into the needs of the China market, with the recent development of an on-premise version of our platform the most notable example."

"We are delighted to announce the addition of Noren to our Board of Directors at this exciting period of growth for GeoSpock. I am hugely impressed with the wealth of knowledge and experience Noren brings to our business, and his expertise will be instrumental in helping to guide the continued expansion and success of GeoSpock. We also thank Parkwalk Advisors for their continued support as we strive to achieve our technological vision across industries spanning mobility, telco, and IoT, as well as smart city and maritime initiatives."

"The new Paragraf facility is a significant step towards realising the potential of graphene in commercially viable, scalable electronic devices, bringing the beneficial impacts of this wonder material to the world."